Adeno-associated Virus Pipeline Assessment (2022): In-depth Analysis of Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, Growth Prospects, and Key Companies

Adeno-associated Virus (AAV) Vectors in Gene Therapy pipeline constitutes 70+ key companies continuously working towards developing 235+ Adeno-associated Virus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Adeno-associated Virus Overview
Adeno-associated virus (AAV) was first discovered from laboratory adenovirus (AdV) preparations in the mid-1960s and Therapy- Overview found in human tissues soon after3. Driven by pure scientific curiosity and without realizing its tremendous potential as a human gene therapy platform, a few research groups embarked on a journey to understand basic AAV biology. During the first 15-20 years of AAV research, several important aspects of AAV were characterized, including its genome configuration and composition, DNA replication and transcription, infectious latency and virion assembly.

"Adeno-associated Virus Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Adeno-associated Virus Market.

The Adeno-associated Virus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Adeno-associated Virus Pipeline Report:
https://www.delveinsight.com/report-store/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

• Companies across the globe are diligently working toward developing novel Adeno-associated Virus treatment therapies with a considerable amount of success over the years. Adeno-associated Virus Key players such as - Asklepios Biopharmaceutical, MeiraGTx, Gyroscope Therapeutics, Nanoscope Therapeutics, Lysogene, Spark Therapeutics, and others, are developing therapies for the Adeno-associated Virus treatment
• Adeno-associated Virus Emerging therapies such as - AAV2/8LSPhGAA, AAV CNGA, GT 005, MCO-010, LYS-SAF302, SPK-9001, SPK-8011, and others are expected to have a significant impact on the Adeno-associated Virus market in the coming years.
• In September 2020, NFS-01 (NR082, rAAV-ND4) was designated as orphan drug by the U.S. FDA, which laid a foundation for accelerating international development of this product.
• In April, 2021 Neurophth announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the Company's Investigational New Drug (IND) applicationofNR082 for LHON patients with ND4 mutations. It marks the first AAV2 gene therapy IND application approval in China
• In November 2021, Neurophth has raised over $60 million in series C financing to advance gene the rapies for ophthalmic diseases. Neurophth is an integrated genomics medicine company whose leading investors include CMG-SDIC Capital, Sequoia Capital China, Sunshine Insurance, and China Merchant BankInternational Capital
• In January 2021, MeiraGTx announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene

Adeno-associated Virus Pipeline Therapeutics Assessment
• Adeno-associated Virus Assessment by Product Type
• Adeno-associated Virus By Stage and Product Type
• Adeno-associated Virus Assessment by Route of Administration
• Adeno-associated Virus By Stage and Route of Administration
• Adeno-associated Virus Assessment by Molecule Type
• Adeno-associated Virus by Stage and Molecule Type

DelveInsight's Adeno-associated Virus Report covers around 235+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Adeno-associated Virus Drugs Under Different Phases of Clinical Development Include:
• AAV2/8LSPhGAA: Asklepios Biopharmaceutical
• AAV CNGA3: MeiraGTx
• GT 005: Gyroscope Therapeutics
• MCO-010: Nanoscope Therapeutics
• MCO-010: Nanoscope Therapeutics
• LYS-SAF302: Lysogene
• SPK-9001: Spark Therapeutics
• SPK-8011: Spark Therapeutics

Get a Free Sample PDF Report to know more about Adeno-associated Virus Pipeline Assessment- https://www.delveinsight.com/sample-request/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Adeno-associated Virus Pipeline Analysis:

The Adeno-associated Virus pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Adeno-associated Virus treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Adeno-associated Virus Treatment.
• Adeno-associated Virus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Adeno-associated Virus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Adeno-associated Virus market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Adeno-associated Virus product details are provided in the report. Download the Adeno-associated Virus pipeline report to learn more about the emerging Adeno-associated Virus therapies at:
https://www.delveinsight.com/sample-request/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Adeno-associated Virus Pipeline Market Drivers
• Increasing incidence of hematological and genetic disorders
• Favorable Research and Development Activities
• Increase in government support, ethical acceptance of gene therapy

Adeno-associated Virus Pipeline Market Barriers
• Multiple technological challenges
• Unwanted immune responses

Scope of Adeno-associated Virus Pipeline Drug Insight
• Coverage: Global
• Key Adeno-associated Virus Companies: Sarepta Therapeutics, Abeona Therapeutics, Forge Biologics, Sangamo therapeutics, Bayer, LogicBio therapeutics, Solid Biosciences, Applied Genetic Technologies, Spark therapeutics (Roche), Eli lilly and company, Lexeo Therapeutics, Spark therapeutics, Gensight Biologics, Alcyone Lifesciences, MeiraGTx, Audentes therapeutics, Vivet Therapeutics, Takeda, Astellas Gene Therapies, Homology Medicines, Adverum Biotechnologies, Libella Gene Therapeutics, Rocket Pharmaceuticals, Brain Neurotherapy Bio, Inc., Ocugen, Asklepios BioPharmaceutical, Neurogene, Jaguar Gene Therapy, LLC, Axovia Therapeutics, Coave therapeutics, Novartis/ Arctos medical, Vedere Bio, REGENXBIO Inc., StrideBio, Abeona therapeutics, Sanofi/ Sirion therapeutics, Capsida Biotherapeutics, Kriya therapeutics, Neurophth, Poseida Therapeutics, BridgeBio Pharma, DiNAQOR/ Biomarin, ViGeneron, AskBio/Selecta Biosciences, Prevail therapeutics, Intas Pharmaceuticals, Tenaya Therapeutics, Scout Bio therapeutics, Ocugen, Oyster Point pharmaceuticals, Cyprium Therapeutics, Solid Biosciences, Amicus Therapeutics, Coave therapeutics, AvantiBio, Voyager Therapeutics/ Pfizer, Aruvant Sciences, Alcyone Lifesciences, Gene Therapy Research Institution Co., Ltd., and others
• Key Adeno-associated Virus Therapies: AAV2/8LSPhGAA, AAV CNGA, GT 005, MCO-010, LYS-SAF302, SPK-9001, SPK-8011, and others
• Adeno-associated Virus Therapeutic Assessment: Adeno-associated Virus current marketed and Adeno-associated Virus emerging therapies
• Adeno-associated Virus Market Dynamics: Adeno-associated Virus market drivers and Adeno-associated Virus market barriers

Request for Sample PDF Report for Adeno-associated Virus Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Adeno-associated Virus Report Introduction
2 Adeno-associated Virus Executive Summary
3 Adeno-associated Virus Overview
4 Adeno-associated Virus- Analytical Perspective In-depth Commercial Assessment
5 Adeno-associated Virus Pipeline Therapeutics
6 Adeno-associated Virus Late Stage Products (Phase II/III)
7 Adeno-associated Virus Mid Stage Products (Phase II)
8 Adeno-associated Virus Early Stage Products (Phase I)
9 Adeno-associated Virus Preclinical Stage Products
10 Adeno-associated Virus Therapeutics Assessment
11 Adeno-associated Virus Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Adeno-associated Virus Key Companies
14 Adeno-associated Virus Key Products
15 Adeno-associated Virus Unmet Needs
16 Adeno-associated Virus Market Drivers and Barriers
17 Adeno-associated Virus Future Perspectives and Conclusion
18 Adeno-associated Virus Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Adeno-associated Virus drugs and therapies- https://www.delveinsight.com/sample-request/adeno-associated-virus-aav-vectors-in-gene-therapy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:

Adeno-associated Virus Market https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Adeno-associated Virus-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom).

Adeno-associated Virus Epidemiology https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Adeno-associated Virus Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Trending Reports:

Diagnostic Imaging Equipment Market
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.


Invasive Candidiasis Market
https://www.delveinsight.com/report-store/invasive-candidiasis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

"DelveInsight's 'Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027' report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW.


Sialidosis Market
https://www.delveinsight.com/report-store/sialidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology, and the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


Filgrastim Biosimilar Insight
https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

DelveInsight's, "Filgrastim Biosimilar Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


Pain Management Devices Market
https://www.delveinsight.com/report-store/pain-management-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027

To know more about our Competitive Services, Click here:
https://www.delveinsight.com/consulting/competitive-intelligence-services?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.